KRAS and colorectal carcinoma: (1) The association between total VC intake and CRC-specific mortality suggestively differed according to KRAS or BRAF mutation status: HR (95% CI), 1.07 (0.87-1.32); (2) in cases with either KRAS or BRAF mutant type: 0.74 (0.55-1.00).